Printer Friendly

EPITOPE REPORTS RESULTS OF STATUS CONFERENCE WITH FDA STAFF REGARDING PENDING APPLICATION

 WASHINGTON, Nov. 10 /PRNewswire/ -- Epitope Inc. (AMEX: EPT) announced that it had a useful and constructive meeting today with FDA's Center for Biologics Evaluation and Research regarding the company's pending premarket approval application for use of its OraSure(R) oral specimen collection device.
 "Certain limited issues remain under active discussion none of which would appear to prevent approval," said Adolph J. Ferro, president and chief executive officer. During the meeting, the company also learned that the application review process is considered to be compete enough so that a facility inspection is now appropriate, he added.
 Epitope is a biotechnology company that develops and markets medical diagnostic products and, through its agricultural units, superior new plants and related products.
 -0- 11/10/93
 /CONTACT: Mary Hagen of Epitope, 503-641-6115/
 (EPT)


CO: Epitope Inc.; Food and Drug Administration, Center for Biologics
 Evaluation and Research ST: Oregon, District of Columbia IN: MTC SU:


IC-RB -- SE020 -- 3015 11/10/93 21:25 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 10, 1993
Words:159
Previous Article:WYSE TO BUNDLE WINDOWS FOR WORKGROUPS 3.11 ON CLIENT AND SERVER PRODUCTS
Next Article:TOTAL SYSTEM SERVICES ANNOUNCES NEGOTIATIONS WITH AMSOUTH BANK
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters